Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0461929603
Tue, 23.12.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
23.12.2025 / 07:00 CET/CEST
Zurich, 23rd of December 2025: Xlife Sciences AG (SIX: XLS) today announced that its Board of Directors has resolved to move from the S [ … ]
Fri, 12.12.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance
Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio
12.12.2025 / 08:30 CET/CEST
Zurich, 12th of December 2025: Xlife Sciences AG (SIX:XLS) is pleased to announce that DAZAmed, the world’s first liver-specific PET tracer, developed in strategic coop [ … ]
Fri, 28.11.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): IPO/Merger
Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
28.11.2025 / 13:10 CET/CEST
Zurich, 28th of November 2025: Xlife Sciences AG («Xlife Sciences», SIX: XLS), a leading incubator and value creator in the life scien [ … ]
Thu, 16.10.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): ESG
Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
16.10.2025 / 07:00 CET/CEST
Zurich, 16th of October 2025: Xlife Sciences AG (SIX: XLS) today announced the publication of its 2024 ESG Report. The report documents the company’s progress in in [ … ]
Thu, 17.07.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): IPO/Merger
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
17.07.2025 / 07:00 CET/CEST
The filing demonstrates continued momentum in VERAXA’s public market journey and billion-dollar valuation
Zurich, 17th of July 20 [ … ]
Tue, 24.06.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): AGMEGM
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
24.06.2025 / 18:00 CET/CEST
Zurich, 24th of June 2025: At today’s Annual General Meeting of Xlife Sciences AG (SIX: XLS), all proposals of the Board of Directors were approved. A total of 3’181’966 voting [ … ]
Mon, 16.06.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance/Partnership
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
16.06.2025 / 16:00 CET/CEST
Zurich, 16th of June 2025: Xlife Sciences AG («Xlife Sciences»SIX: XLS), a Swiss-based incub [ … ]
Fri, 13.06.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance/Partnership
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets
13.06.2025 / 17:42 CET/CEST
Zurich, 13th of June 2025: Xlife Sciences AG («Xlife Sciences», SIX: XLS), a Swiss-based [ … ]
Tue, 06.05.2025
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Alliance/Partnership
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy
06.05.2025 / 07:00 CET/CEST
Zurich, 6th of May 2025: Xlife Sciences AG («Xlife Sciences»; SIX:XLS) is proud to announce a st [ … ]
